• Genetic testing should be a standard component of prostate cancer care to improve treatment decisions and early detection.
• Germline and somatic testing, combined with PSMA-PET imaging, offers a comprehensive approach to detecting and treating prostate cancer early.
• Urologists should adhere to guideline recommendations from organizations like NCCN and EUA to ensure optimal patient care.

At the 2025 American Urological Association (AUA) Annual Meeting in Las Vegas, Nevada, Joy Maulik, CRNP, a urology nurse practitioner at Chesapeake Urology, advocated for the wider adoption of genetic testing in prostate cancer management. Maulik's argument centers on the potential of genetic insights, derived from germline and somatic testing, to enhance early disease detection and inform treatment strategies, ultimately leading to improved patient outcomes. Maulik emphasized that incorporating genetic testing is essential for providing comprehensive and effective care.

• What: Joy Maulik, CRNP, is advocating for the incorporation of genetic testing as a routine part of prostate cancer care, including germline and somatic testing.
• Who: Joy Maulik, CRNP, Chesapeake Urology, urologists, patients with prostate cancer.
• When: Discussion took place at the 2025 American Urological Association (AUA) Annual Meeting.
• Where: Las Vegas, Nevada.

The argument presented by Joy Maulik highlights a potential gap in current prostate cancer management practices. While genetic testing offers significant advantages in early detection and personalized treatment, its underutilization by urologists represents a missed opportunity. Maulik's call for increased adoption of genetic testing aligns with the growing trend towards precision medicine in oncology, which emphasizes tailoring treatment strategies based on individual patient characteristics. The reference to NCCN and EUA guidelines underscores the importance of evidence-based practices and staying current with evolving standards of care.

I truly think genetic testing should be incorporated as a part of daily care in prostate cancer.

If we don't do it, I think we are not taking care of the patient the right way that we need to.

We should be looking at what NCCN guidelines are. We should be looking at what EUA is doing, because cancer doesn't have emotion. No matter which continent it's hitting you, it's hitting you.

Joy Maulik's advocacy for increased genetic testing in prostate cancer represents a significant step towards improving patient care. By emphasizing the importance of germline and somatic testing, alongside adherence to established guidelines, Maulik highlights a pathway for urologists to enhance early detection, personalize treatment strategies, and ultimately improve outcomes for individuals affected by prostate cancer. The ongoing evolution of genetic testing technologies and treatment approaches suggests that Maulik's recommendations will continue to gain relevance in the future.